Gene therapy for primary immunodeficiencies

Current Opinion in Pediatrics

Volumn 24, Issue 6, 2012, Pages 731-738

  Kildebeck, Eric ^a,b   Checketts, Josh ^a,b   Porteus, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

gene targeting; gene therapy; homologous recombination; primary immunodeficiencies; transcription activator like effector nucleases; zinc finger nucleases

Indexed keywords

GENE THERAPY AGENT; LENTIVIRUS VECTOR; ZINC FINGER NUCLEASE;

CLINICAL TRIAL (TOPIC); GENE TARGETING; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; GENETIC THERAPY; GENETIC VECTORS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES;

EID: 84870056877     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328359e480     Document Type: Review

References (59)

1. Booth C, Gaspar HB, Thrasher AJ. Gene therapy for primary immunodeficiency. Curr Opin Pediatr 2011; 23:659-666.
2. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995; 270:475-480.
3. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363:355-364.
4. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360:447-458.
5. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med 2011; 3:97ra80.
6. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3:97ra79.
7. Boztug K, Schmidt M, Schwarzer A, et al. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med 2010; 363:1918-1927.
8. Kang HJ, Bartholomae CC, Paruzynski A, et al. Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial. Mol Ther 2011; 19:2092-2101.
9. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet 2011; 12:301-315.
10. Cattoglio C, Pellin D, Rizzi E, et al. High-definition mapping of retroviral integration sites identifies active regulatory elements in human multipotent hematopoietic progenitors. Blood 2010; 116:5507-5517.
11. Cooray S, Howe SJ, Thrasher AJ. Retrovirus and lentivirus vector design and methods of cell conditioning. Methods Enzymol 2012; 507:29-57.
12. Pike-Overzet K, Rodijk M, Ng YY, et al. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer. Leukemia 2011; 25:1471-1483.
13. Santilli G, Almarza E, Brendel C, et al. Biochemical correction of X-CGD by a novel chimeric promoter regulating high levels of transgene expression in myeloid cells. Mol Ther 2011; 19:122-132.
14. Astrakhan A, Sather BD, Ryu BY, et al. Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome. Blood 2012; 119:4395-4407.
15. van Til NP, de Boer H, Mashamba N, et al. Correction of Murine Rag2 Severe Combined Immunodeficiency by Lentiviral Gene Therapy Using a Codon-optimized RAG2 Therapeutic Transgene. Mol Ther 2012. [Epub ahead ofprint]
16. Avedillo Diez I, Zychlinski D, Coci EG, et al. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm 2011; 8:1525-1537.
17. Scaramuzza S, Biasco L, Ripamonti A, et al. Preclinical Safety and Efficacy of Human CD34 Cells Transduced With Lentiviral Vector for the Treatment of Wiskott-Aldrich Syndrome. Mol Ther 2012. [Epub ahead of print]
18. Huston MW, van Til NP, Visser TP, et al. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol Ther 2011; 19:1867-1877.
19. Zhang F, Frost AR, Blundell MP, et al. A ubiquitous chromatin opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral vectors. Mol Ther 2010; 18:1640-1649.
20. Ng YY, Baert MR, Pike-Overzet K, et al. Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK. Leukemia 2010; 24:1617-1630.
21. Hunter MJ, Tuschong LM, Fowler CJ, et al. Gene therapy of canine leukocyte adhesion deficiency using lentiviral vectors with human CD11b and CD18 promoters driving canine CD18 expression. Mol Ther 2011; 19:113-121.
22. Moreno-Carranza B, Gentsch M, Stein S, et al. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther 2009; 16:111-118.
23. Abstracts of the American Society of Gene & Cell Therapy 15th Annual Meeting;16-19 May 2012; Philadelphia, Pennsylvania, USA. Mol Ther 2012; 20 (Suppl 1):S1-S322.
24. Rivat C, Santilli G, Gaspar HB, Thrasher A. Gene therapy for primary immunodeficiencies (PIDs). Hum Gene Ther 2012; 23:668-675.
25. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 2010; 467:318-322.
26. Lombardo A, Genovese P, Beausejour CM, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol 2007; 25:1298-1306.
27. Munoz IG, Prieto J, Subramanian S, et al. Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res 2011; 39:729-743.
28. Zou J, Sweeney CL, Chou BK, et al. Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood 2011; 117:5561-5572.
29. Rouet P, Smih F, Jasin M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci U S A 1994; 91:6064-6068.
30. Porteus MH, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003; 300:763.
31. Urnov FD, Miller JC, Lee YL, et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435:646-651.
32. van Rensburg R, Beyer I, Yao XY, et al. Chromatin structure of two genomic sites for targeted transgene integration in induced pluripotent stem cells and hematopoietic stem cells. Gene Ther 2012. [Epub ahead of print]
33. Zou J, Maeder ML, Mali P, et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 2009; 5:97-110.
34. Lombardo A, Cesana D, Genovese P, et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 2011; 8:861-869.
35. Connelly JP, Barker JC, Pruett-Miller S, Porteus MH. Gene correction by homo logous recombination with zinc finger nucleases in primary cells from a mouse modelofa generic recessive geneticdisease. Mol Ther 2010; 18:1103-1110.
36. Li H, Haurigot V, Doyon Y, et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011; 475:217-221.
37. Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009; 326:1509-1512.
38. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science 2009; 326:1501.
39. Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011; 29:143-148.
40. Streubel J, Blucher C, Landgraf A, Boch J. TAL effector RVD specificities and efficiencies. Nat Biotechnol 2012; 30:593-595.
41. Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4 T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008; 26:808-816.
42. Holt N, Wang J, Kim K, et al. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010; 28:839-847.
43. Sander JD, Dahlborg EJ, Goodwin MJ, et al. Selection-free zinc-finger-nucle-ase engineeringby context-dependent assembly (CoDA). Nat Methods 2011; 8:67-69.
44. Mussolino C, Cathomen T. TALE nucleases: tailored genome engineering made easy. Curr Opin Biotechnol 2012. [Epub ahead of print]
45. Christian M, Cermak T, Doyle EL, et al. Targeting DNA double-strand breaks with TAL effector nucleases. Genetics 2010; 186:757-761.
46. Mussolino C, Morbitzer R, Lutge F, et al. A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity. Nucleic Acids Res 2011; 39:9283-9293.
47. Cermak T, Doyle EL, Christian M, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res 2011; 39:e82.
48. Reyon D, Tsai SQ, Khayter C, et al. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol 2012; 30:460-465.
49. Briggs AW, Rios X, Chari R, et al. Iterative capped assembly: rapid and scalable synthesis of repeat-module DNA such as TAL effectors from in dividual monomers. Nucleic Acids Res 2012; 40:e117.
50. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011; 29:731-734.
51. Wood AJ, Lo TW, Zeitler B, et al. Targeted genome editing across species using ZFNs and TALENs. Science 2011; 333:307.
52. Sun N, Liang J, Abil Z, Zhao H. Optimized TAL effector nucleases (TALENs) for use in treatment of sickle cell disease. Mol Biosyst 2012; 8:1255-1263.
53. Brunet E, Simsek D, Tomishima M, et al. Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci U S A 2009; 106:10620-10625.
54. Chiarle R, Zhang Y, Frock RL, et al. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. Cell 2011; 147:107-119.
55. Gabriel R, Lombardo A, Arens A, et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 2011; 29:816-823.
56. Pattanayak V, Ramirez CL, Joung JK, Liu DR. Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat Methods 2011; 8:765-770.
57. Deng D, Yan C, Pan X, et al. Structural basis for sequence-specific recogni-tion of DNA by TAL effectors. Science 2012; 335:720-723.
58. Mak AN, Bradley P, Cernadas RA, et al. The crystal structure of TAL effector PthXo1 bound to its DNA target. Science 2012; 335:716-719.
59. Doyon Y, Vo TD, Mendel MC, et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat Methods 2011; 8:74-79.